Real-world Experience of Abrocitinib on Difficult-to-treat Hand Eczema in Chinese Patients
DOI:
https://doi.org/10.2340/actadv.v104.39822Keywords:
Abrocitinib, Efficacy, Hand eczema, SafetyAbstract
Abstract is missing (Short communication)
Downloads
References
Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol 2020; 34: 4-12.
https://doi.org/10.1111/jdv.16061 DOI: https://doi.org/10.1111/jdv.16061
Marron SE, Tomas-Aragones L, Navarro-Lopez J, Gieler U, Kupfer J, Dalgard FJ, et al. The psychosocial burden of hand eczema: data from a European dermatological multicentre study. Contact Dermatitis 2018; 78: 406-412.
https://doi.org/10.1111/cod.12973 DOI: https://doi.org/10.1111/cod.12973
Quaade AS, Alinaghi F, Dietz JB, Erichsen CY, Johansen JD. Chronic hand eczema: a prevalent disease in the general population associated with reduced quality of life and poor overall health measures. Contact Dermatitis 2023; 89: 453-463.
https://doi.org/10.1111/cod.14407 DOI: https://doi.org/10.1111/cod.14407
Cheng J, Facheris P, Ungar B, Guttman-Yassky E. Current emerging and investigational drugs for the treatment of chronic hand eczema. Expert Opin Investig Drugs 2022; 31: 843-853.
https://doi.org/10.1080/13543784.2022.2087059 DOI: https://doi.org/10.1080/13543784.2022.2087059
Worm M, Thyssen JP, Schliemann S, Bauer A, Shi VY, Ehst B, et al. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial. Br J Dermatol 2022; 187: 42-51.
https://doi.org/10.1111/bjd.21037 DOI: https://doi.org/10.1111/bjd.21037
Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, et al. Oral spleen tyrosine kinase/Janus kinase inhibitor gusacitinib for the treatment of chronic hand eczema: results of a randomized phase 2 study. J Am Acad Dermatol 2023; 89: 235-242.
https://doi.org/10.1016/j.jaad.2023.04.027 DOI: https://doi.org/10.1016/j.jaad.2023.04.027
Rosenberg FM, Loman L, Schuttelaar MLA. Baricitinib treatment of severe chronic hand eczema: two case reports. Contact Dermatitis 2022; 86: 419-421.
https://doi.org/10.1111/cod.14039 DOI: https://doi.org/10.1111/cod.14039
Zalewski A, Szepietowski JC. Topical and systemic JAK inhibitors in hand eczema: a narrative review. Expert Rev Clin Immunol 2023; 19: 365-373.
https://doi.org/10.1080/1744666X.2023.2174526 DOI: https://doi.org/10.1080/1744666X.2023.2174526
Vazquez ML, Kaila N, Strohbach JW, Trzupek JD, Brown MF, Flanagan ME, et al. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem 2018; 61: 1130-1152.
https://doi.org/10.1021/acs.jmedchem.7b01598 DOI: https://doi.org/10.1021/acs.jmedchem.7b01598
Sitaru S, Preis S, Eberlein B. Successful treatment of atopic hand and foot eczema with oral Janus kinase 1 inhibition. Dermatitis 2023; 34: 560.
https://doi.org/10.1089/derm.2022.0030 DOI: https://doi.org/10.1089/derm.2022.0030
Kamphuis E, Boesjes CM, Loman L, Kamsteeg M, Haeck I, Van Lynden-van Nes AMT, et al. Real-world experience of abrocitinib treatment in patients with atopic dermatitis and hand eczema: up to 28-week results from the BioDay Registry. Acta Derm Venereol 2024; 104: adv19454.
https://doi.org/10.2340/actadv.v104.19454 DOI: https://doi.org/10.2340/actadv.v104.19454
Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis 2022; 86: 357-378.
https://doi.org/10.1111/cod.14035 DOI: https://doi.org/10.1111/cod.14035
Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Br J Dermatol 2005; 152: 302-307.
https://doi.org/10.1111/j.1365-2133.2004.06305.x DOI: https://doi.org/10.1111/j.1365-2133.2004.06305.x
Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol 2016; 74: 288-294.
https://doi.org/10.1016/j.jaad.2015.09.062 DOI: https://doi.org/10.1016/j.jaad.2015.09.062
Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol 2015; 54: 715-722
https://doi.org/10.1111/ijd.12645 DOI: https://doi.org/10.1111/ijd.12645
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Yiting Li, Xi Tan, Shu Nie, Xin Tian, Zhouwei Wu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
